Trial Profile
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms OPERA I
- Sponsors Roche
- 13 Oct 2023 Results (n=933 from OPERA I/II; NCT01247324/NCT01412333 vs ORATORIO; NCT01194570) assessing combined measure for assessing the risk of long-term progression at earlier time points presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2023 Results assessing the long-term impact of ocrelizumab on disability accumulation in patients with RMS and PPMS from OPERA I/II (NCT01247324/NCT01412333), ORATORIO (NCT01194570) and OLERO (NCT05269004) studies, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
- 12 Oct 2023 Results presented in the Roche media release.